Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

TAK-341 · MEDI-1341

Other · developed by TAKEDA PHARMACEUTICAL CO

Phase 2 Most advanced trial (none active)
TAK Developer
1 Registered trials

What is TAK-341?

TAK-341 is an investigational drug studied in Multiple System Atrophy.

At a glance

Also known as
MEDI-1341
Drug type
Other
Therapy area
Neurology
Developer
TAKEDA PHARMACEUTICAL CO (TAK)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
2RIB5BB8CX

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05526391 Phase 2 Multiple System Atrophy Completed TAK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Multiple System Atrophy

More from TAKEDA PHARMACEUTICAL CO

Maribavir FDA approved Susoctocog Alfa FDA approved Vedolizumab FDA approved Vonicog Alfa FDA approved Elritercept Phase 3 GDX012 Phase 1/2 IGI Phase 3 Mezagitamab Phase 3 MNI-792 Phase 1 Pevonedistat Phase 2/3 Soticlestat Phase 3 TAK-186 Phase 1/2

Follow TAK, the company behind TAK-341

See TAK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TAK catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.